Is It Time To Reassess 10x Genomics (TXG) After Its Recent Share Price Surge?

Endpoints NewsTessera reveals strongest data yet for in vivo sickle cell therapy

BioPharma Dive[Podcast] Closing the Distance in Cancer Care

Endpoints NewsMerck KGaA's clients are stockpiling due to Iran war, supporting guidance boost

CellImage-based, pooled phenotyping reveals multidimensional, disease-specific variant effects

CellD-SPIN constructs regulatory network models from scRNA-seq that reveal organizing principles of perturbation response

CellDiscovery and heterologous reconstitution of a plant noncanonical quasi-circadian gene regulatory network

CellGalvanin (TMEM154) is an electric-field sensor for directed cell migration

FierceBiotechTakeda 0 for 4 against nausea and vomiting after axing another asset

LabiotechTIL therapies: the impact on cancer research

FierceBiotechAstraZeneca pens agentic AI licensing deal with Owkin

10x Genomics BlogIs It Time To Reassess 10x Genomics (TXG) After Its Recent Share Price Surge? - Yahoo Finance

10x Genomics BlogWhy 10x Genomics (TXG) Stock Is Down Today - Yahoo Finance